The Center for Biosimilars® recaps the top stories for the week of January 20, 2020.
Hi, I’m Gianna Melillo for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of January 20, 2020
Number 5: Celltrion announces that it plans to launch 10 biosimilars over the next decade and will also open a large biologics manufacturing plant in China.
Number 4: A healthcare executive writes that providers should be able to help their patients reduce their out-of-pockets costs while providing the highest-quality care available through oncology biosimilars.
Number 3: Alvotech and JAMP Pharma announce a partnership to commercialize 5 biosimilars in the Canadian market.
Number 2: Gilead Science’s new chairman and chief executive officer outlines a growth plan at the J.P. Morgan Healthcare Conference.
Number 1: Teva Pharmaceuticals touts the launch of its biosimilar rituximab, Truxima, as evidence that it knows how to navigate the US pharmaceutical system.
To read all of these articles and more, visit centerforbiosimilars.com.